An interventional study of Immediate Oral Antibiotics and Tailored Treatment: Oral Antibiotics only if Additional Treatment needed in Cystic Fibrosis, sponsored by University of Washington, the Collaborative Health Studies Coordinating Center. Recruiting at 33 sites in 2 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Washington, the Collaborative Health Studies Coordinating Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 24th largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 155 with no phase, reaches primary completion later than 68 of the 108 other live ones, and was the 682nd registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 30 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
University of Washington, the Collaborative Health Studies Coordinating Center is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
University of Washington, the Collaborative Health Studies Coordinating Center has 5 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
Highly Effective Modulator Therapy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Increased airway clearance plus early initiation of oral antibiotics
Other: Immediate Oral Antibiotics
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve
Other: Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Increase airway clearance and start 14 days of preselected oral antibiotics right away
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
One-year change in pulmonary function by spirometry-measured ppFEV1
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.
Time frame: 1 year
One-Year change in pulmonary function by LCI
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level.
Time frame: 1 year
Recovery to baseline by ppFEV1 and CRISS following a PEx
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 28 days
Recovery to baseline by Lung Clearance Index (LCI)
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 28 days
Safety Endpoint 1: Cumulative oral antibiotic exposure
Compare cumulative oral antibiotic exposure in each treatment arm.
Time frame: 1 year
Safety Endpoint 2: Number of respiratory illnesses
Compare the number of respiratory illnesses reported over the study period in each treatment arm.
Time frame: 1 year
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm.
Time frame: 28 days
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm.
Time frame: 1 year
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm.
Time frame: 28 days
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm.
Time frame: 1 year
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm.
Time frame: 1 year
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm.
Time frame: 1 year
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm.
Time frame: 1 year
Qualitative Assessment 1: Caregivers' experience managing study treatment
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences.
Time frame: 1 year
Qualitative Assessment 2: Study treatment impact on child and family daily life
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences.
Time frame: 1 year
Health care costs 1: Total estimated cost of antibiotics
Compare total estimated cost of antibiotics used over the course of the study between treatment arms.
Time frame: 1 year
Health care costs 2: Health care utilization
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits.
Time frame: 1 year
Health care costs 3: Parent work productivity measures (WPAI)
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment.
Time frame: 1 year
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx).
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Measure the proportion of approached patients that enrolls.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Measure the proportion of respiratory symptoms meeting randomization criteria.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm.
Time frame: 28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm.
Time frame: 28 days
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms.
Time frame: 1 year
Clinic Throat Swab Substudy 2: Microbiota Measures
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments.
Time frame: 1 year
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis.
Time frame: 28 days
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx).
Time frame: 28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28.
Time frame: 28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment.
Time frame: 28 days
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy.
Time frame: 28 days
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study.
Time frame: 28 days
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study.
Time frame: 14 days
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28).
Time frame: 28 days
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state.
Time frame: 28 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state.
Time frame: 14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state.
Time frame: 14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state.
Time frame: 14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Describe changes in sleep time from Day 0 to 14 of the exacerbation state.
Time frame: 14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Compare changes in resting HR to averages from a 7-day period during baseline state.
Time frame: 14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state.
Time frame: 14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state.
Time frame: 14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state.
Time frame: 14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.
Time frame: 14 days
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 36 months is above that.
Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Washington, the Collaborative Health Studies Coordinating Center